Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

ABSTRACT:

Purpose

To evaluate the safety and tolerability of intraocular delivery of ciliary neurotrophic factor (CNTF) using an encapsulated cell implant for the treatment of macular telangiectasia type 2.

Design

An open-label safety trial conducted in 2 centers enrolling 7 participants with macular telangiectasia type 2.

Methods

The participant's more severely affected eye (worse baseline visual acuity) received the high-dose implant of CNTF. Patients were followed for a period of 36 months. The primary safety outcome was a change in the parameters of the electroretinogram (ERG). Secondary efficacy outcomes were changes in visual acuity, en face measurements of the optical coherence tomography of the disruption in the ellipsoid zone, and microperimetry when compared with base

SUBMITTER: Chew EY 

PROVIDER: S-EPMC4361328 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature